Left Atrial Appendage Closure

In patients with atrial fibrillation, abnormal and chaotic electrical signals or pathways occur in the atria (upper chambers of the heart), causing an irregular heartbeat and keeping the atria from contracting or squeezing normally. The atria quiver instead, lowering the amount of blood ejected from the heart with each heartbeat.

For years, the Center for Heart Rhythm Disorders at Northwestern Medicine Bluhm Cardiovascular Institute has provided a variety of ways to treat atrial fibrillation, including medication, catheter ablation and surgery. Today, Bluhm Cardiovascular Institute offers a minimally invasive procedure that may reduce a patient’s need for ongoing medical treatment with blood thinners.

What is the left atrial appendage?
The heart has four chambers, two on top and two on the bottom. The left atrium is the upper left chamber of the heart. The left atrial appendage is a pocket-like section in the left atrium of the heart.

The left atrial appendage is not a highly necessary part of the heart. In fact, it is often a source of blood clot formation and may cause up to 90 percent of strokes due to atrial fibrillation. Closing the left atrial appendage can prevent blood clots from escaping and causing a stroke.

The WATCHMAN® procedure
In the WATCHMAN® procedure, a small device is inserted into the left atrial appendage to act as a plug, cutting off blood flow and reducing risk of blood clots and stroke. While patients are required to use blood thinners for at least 45 days after the procedure, they often can stop taking medication later.

The WATCHMAN® procedure has been found just as effective as anticoagulants for stroke prevention.

Northwestern Memorial Hospital was the first hospital in Illinois to successfully place the WATCHMAN® Left Atrial Appendage Closure (LAAC) device in a patient after the recent approval of the device by the Food and Drug Administration (FDA).

Benefits of treatment
The WATCHMAN® procedure is minimally invasive, and most patients can return home the next day. The goal of this procedure is to offer patients a reduction in chance of stroke and, for many, the chance to stop taking blood thinners altogether.

Who qualifies for treatment?
Men and women with atrial fibrillation with risk factors for stroke who are having trouble managing their anticoagulation medication, have experienced bleeding while on blood thinners, or who can’t take blood thinners at all may be candidates for treatment.

Clinical trials

Physicians and researchers at Bluhm Cardiovascular Institute conduct clinical research trials on all aspects of heart and vascular disease, including atrial fibrillation and left atrial appendage closure. For more information regarding cardiovascular clinical trials:

Meet the Left Atrial Appendage Closure Team

Northwestern Medicine Bluhm Cardiovascular Institute is a nationally recognized destination for those who require highly specialized cardiovascular care. Meet the Teams
Downtown Chicago
Northern Suburbs
Western Suburbs
Greater DeKalb County
Northwest Suburbs